CYCLOPHARM LIMITED (CYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CYC

CYC - CYCLOPHARM LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.64
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.635

03 Nov
2025

-0.035

OPEN

$0.64

-5.22%

HIGH

$0.64

7,478

LOW

$0.63

TARGET
$1.50 136.2% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CYC: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 12.8 - 10.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/09 - ex-div 0.5c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-12.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx27.6 M
Book Value Per Share xxxxxxxxxxxxxxx38.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-12.6 M
Net Profit Margin xxxxxxxxxxxxxxx-47.87 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-35.20 %
Return on Invested Capital xxxxxxxxxxxxxxx-30.46 %
Return on Assets xxxxxxxxxxxxxxx-24.43 %
Return on Equity xxxxxxxxxxxxxxx-35.20 %
Return on Total Capital xxxxxxxxxxxxxxx-33.20 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-13.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx8 M
Total Debt xxxxxxxxxxxxxxx8 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx21 M
Price To Book Value xxxxxxxxxxxxxxx4.12

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx3.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx27 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx15 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

29/08/2025

1

Buy

$1.50

136.22%

Cyclopharm's interim revenue of $15.4m came in -3% below Bell Potter’s $15.8m forecast. US sales of $1.2m missed the broker’s $1.8m estimate on a slower rollout, while distributor revenue rose 58% to $7.8m, around 29% above forecasts.

Operating expenses increased/deteriorated by -12% and lower margins led to an -$8m earnings loss, explain the analysts, with a net loss at -$7.7m.

Cash burn rose to -$7.5m, leaving $12.4m cash at June, cautions Bell Potter, though asset sales are expected to add $6.2m in the second half, lifting pro-forma cash to around $18.6m. 

The broker cuts its FY25 and FY26 profit forecasts by -20% and -21%, respectively. The analysts point to sluggish US momentum, yet also note management’s reiterated guidance for 250-300 devices installed by end-2026 from the current 35.

The target price is lowered to $1.50 from $2.20. Bell Potter retains a Buy rating.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -10.30 cents.
Bell Potter forecasts a full year FY26 dividend of 1.00 cents and EPS of minus -6.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

CYC STOCK CHART

FNArena News on CYC

1
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia
2
FNArena Corporate Results Monitor – 26-02-2025

Feb 26 2025 - Australia
3
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View
4
Rudi’s View: Banks, WiseTech, Redox & Integral Diagnostics

Dec 19 2024 - Rudi's View
5
Rudi’s View: Best Buys & Smaller Cap Favourites

Dec 12 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
2
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
3
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
4
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
5
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
6
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
7
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
8
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
9
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
10
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia